10th Dermatology Drug Development Summit

10th Dermatology Drug Development Summit – Discovering, Developing & Commercializing Next-Generation Inflammatory Skin Disease Therapeutics – November 3-5, 2026 | Boston, MA

The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflammatory skin disease.

Marking a decade of convening the field’s most influential voices, this year’s summit arrives at a pivotal moment: As competition intensifies across atopic dermatitis and psoriasis, developers are under growing pressure to demonstrate meaningful differentiation, accelerate development timelines and identify the next generation of high-value opportunities beyond today’s established targets and therapies.

Designed as an intimate, discussion-led forum, the summit brings together more than 90 experts spanning discovery, translational medicine, preclinical development, clinical strategy, medical affairs, and commercial functions.

The meeting provides a unique opportunity to benchmark emerging science, evaluate novel targets, and share practical lessons from across the dermatology pipeline.

Attendees will hear from 40+ senior leaders representing major pharmaceutical companies, innovative biotechs, academic research centers, and patient advocacy organizations, with representation from AbbVie, Galderma, Merck, SUN Pharma, Eli Lilly, UNION Therapeutics and others.

This year’s agenda features dual content tracks including Discovery & Preclinical and Clinical & Commercial.

New additions include a Pre-Conference Workshop Day,  offering interactive deep dives into two of dermatology’s fastest-growing areas of innovation: hidradenitis suppurativa, exploring strategies to drive earlier intervention and disease modification, and rare & ultra-rare inflammatory skin diseases, examining how developers can generate meaningful evidence, overcome translational challenges and unlock scalable opportunities across underserved patient populations.

With 10+ hours of in-person networking, the summit fosters meaningful collaboration among scientists, clinicians, executives, and decisionmakers working to discover, develop and commercialize the next wave of precision therapeutics.

For organizations committed to shaping the future of inflammatory skin disease drug development, the Dermatology Drug Development Summit remains the essential annual meeting to align on emerging science, evolving standards of care, and the path to impactful patient outcomes.

Find out more about the 10^th Anniversary Edition of the Dermatology Drug Development Summit: https://ter.li/rcr0mcj